Drug profile · INN
diflunisal
ATTROGY
diflunisal (ATTROGY) is a cyclooxygenase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — diflunisal
- US status
- approved
- Class
- Nervous system (N02)
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.89
Quick answer
diflunisal (ATTROGY) is a cyclooxygenase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Cyclooxygenase inhibitor
Primary target: Cyclooxygenase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is diflunisal?
diflunisal (ATTROGY) is a cyclooxygenase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for diflunisal?
ATTROGY is a marketed brand name for diflunisal. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of diflunisal?
diflunisal has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.